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Investigating Gαs pepducin’s effect on β2AR signaling for CHF pharmacology 
Introduction: Congestive heart failure affects nearly six million Americans and significantly 
impairs their quality of life. New and better interventions are needed to improve HF patients’ 
survival and outcomes. Pharmacologics that bias β2AR signaling towards arrestin, which 
promotes cardiomyocyte survival and contractility, may offer advantages over traditional β-
blockers. 
Objective: It has been demonstrated that peptides mimicking the C-terminus of the Gαs subunit 
block downstream signaling of GPCRs. The study’s objective is to determine if a pepducin 
derived from the C-terminus of the Gαs subunit of the β2AR could block Gs signaling but 
maintain arrestin-recruitment, thereby producing a cardioprotective phenotype. 
Methods: We used inverse PCR and bacterial transformation to design the peptide. We 
transfected Chinese hamster ovary (CHO) cells with the pepducin and used FACS and Glosensor 
assays to measure the concentration of cAMP in various cells. 
Results: Results showed no inhibition of Gs signaling. Therefore, arrestin-recruitment was not 
tested.  
Discussion: Previous researchers have demonstrated the results we failed to show, therefore we 
have reason to believe the peptide failed to inhibit Gs signaling because it is too small or too 
unstable. We are abandoning this line of research and will be continuing to approach the 
project’s objective from new angles. 
  
